A biosimilar’s developmental pathway: the final analysis of GP2013
The changing landscape of NSCLC diagnosis, monitoring and treatment
Combining agents to improve response rates in genitourinary cancer
Andrea B. Apolo
What is durvalumab’s future as a treatment option in lung cancer?
Differences in the number of clinical trials for melanoma and squamous cell carcinoma